ImmunityBio
IBRX
47 hedge funds and large institutions have $6.47M invested in ImmunityBio in 2019 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 8 increasing their positions, 20 reducing their positions, and 18 closing their positions.
3.68% less ownership
Funds ownership: 10.1% → 6.42% (-3.7%)
19% less funds holding
Funds holding: 58 → 47 (-11)
50% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 18
53% less capital inflows, than outflows
Capital inflows: $1.78M | Capital outflows: $3.76M
60% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 20
98% less call options, than puts
Call options by funds: $1K | Put options by funds: $53K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$921K |
| 2 |
Renaissance Technologies
New York
|
+$323K |
| 3 |
Paloma Partners
Greenwich,
Connecticut
|
+$143K |
| 4 |
Jane Street
New York
|
+$104K |
| 5 |
Goldman Sachs
New York
|
+$88.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$1.55M |
| 2 |
State Street
Boston,
Massachusetts
|
-$453K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$446K |
| 4 |
Bridgeway Capital Management
Houston,
Texas
|
-$318K |
| 5 |
DekaBank Deutsche Girozentrale
Frankfurt,
Germany
|
-$107K |
IBRX Hedge Fund Activity: Q2 2019 in Review
47 of the 4,626 institutional investors tracked by Wall St. Rank reported a position in ImmunityBio (IBRX) for Q2 2019, worth a combined $6.47M — down 49% from $12.7M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of IBRX and 9 opened new positions — a net loss of 9 holders — while 20 trimmed existing stakes and 8 added.
The largest buyer was Millennium Management, adding an estimated $921K. The largest seller was BlackRock, cutting an estimated $1.55M.
- 47 institutional investors held ImmunityBio (IBRX) as of Q2 2019, down from 58 in Q1 2019.
- Funds reported $6.47M of ImmunityBio stock for Q2 2019, down 49% quarter-over-quarter.
- 9 funds opened new ImmunityBio positions in Q2 2019 and 18 closed out, a net change of -9 holders.
- The largest ImmunityBio buyer in Q2 2019 was Millennium Management, an estimated $921K added.
- The largest ImmunityBio seller in Q2 2019 was BlackRock, an estimated $1.55M sold.
Based on aggregated 13F filings for Q2 2019.